BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 11776376)

  • 21. T-cell immunotherapy for human MK-1-expressing tumors using a fusion protein of the superantigen SEA and anti-MK-1 scFv antibody.
    Ueno A; Arakawa F; Abe H; Matsumoto H; Kudo T; Asano R; Tsumoto K; Kumagai I; Kuroki M; Kuroki M
    Anticancer Res; 2002; 22(2A):769-76. PubMed ID: 12014649
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Solid tumor-targeted infiltrating cytotoxic T lymphocytes retained by a superantigen fusion protein.
    Sun J; Zhao L; Teng L; Lin F; Zhang H; Li Z; Gao Q
    PLoS One; 2011 Feb; 6(2):e16642. PubMed ID: 21311755
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Superantigen-induced human CD4+ helper/killer T cell phenomenon. Selective induction of Th1 helper/killer T cells and application to tumor immunotherapy.
    Kuge S; Miura Y; Nakamura Y; Mitomi T; Habu S; Nishimura T
    J Immunol; 1995 Feb; 154(4):1777-85. PubMed ID: 7836762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. T-cell stimulation and cytokine release induced by staphylococcal enterotoxin A (SEA) and the SEAD227A mutant.
    Holzer U; Orlikowsky T; Zehrer C; Bethge W; Dohlsten M; Kalland T; Niethammer D; Dannecker GE
    Immunology; 1997 Jan; 90(1):74-80. PubMed ID: 9038715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A highly effective and stable bispecific diabody for cancer immunotherapy: cure of xenografted tumors by bispecific diabody and T-LAK cells.
    Hayashi H; Asano R; Tsumoto K; Katayose Y; Suzuki M; Unno M; Kodama H; Takemura S; Yoshida H; Makabe K; Imai K; Matsuno S; Kumagai I; Kudo T
    Cancer Immunol Immunother; 2004 Jun; 53(6):497-509. PubMed ID: 14648071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1.
    Kawaoka T; Oka M; Takashima M; Ueno T; Yamamoto K; Yahara N; Yoshino S; Hazama S
    Oncol Rep; 2008 Jul; 20(1):155-63. PubMed ID: 18575732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monoclonal antibody-superantigen fusion proteins: tumor-specific agents for T-cell-based tumor therapy.
    Dohlsten M; Abrahmsén L; Björk P; Lando PA; Hedlund G; Forsberg G; Brodin T; Gascoigne NR; Förberg C; Lind P
    Proc Natl Acad Sci U S A; 1994 Sep; 91(19):8945-9. PubMed ID: 8090750
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Co-stimulation with B7 and targeted superantigen is required for MHC class II-independent T-cell proliferation but not cytotoxicity.
    Lando PA; Dohlsten M; Hedlund G; Brodin T; Sansom D; Kalland T
    Immunology; 1993 Oct; 80(2):236-41. PubMed ID: 7505257
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody-directed superantigen-mediated T-cell killing of myeloid leukaemic cell line cells.
    Gidlöf C; Carlson B; Dohlsten M; Tötterman TH
    Eur J Haematol; 1998 Apr; 60(4):233-9. PubMed ID: 9579876
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulation of superantigen-induced T cell activation in the absence and the presence of MHC class II.
    Lando PA; Olsson C; Kalland T; Newton D; Kotb M; Dohlsten M
    J Immunol; 1996 Oct; 157(7):2857-63. PubMed ID: 8816390
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A natural mutation of the amino acid residue at position 60 destroys staphylococcal enterotoxin A murine T-cell mitogenicity.
    Mahana W; al-Daccak R; Lévéillé C; Valet JP; Hébert J; Ouellette M; Mourad W
    Infect Immun; 1995 Aug; 63(8):2826-32. PubMed ID: 7622202
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bacterial superantigens as anti-tumour agents: induction of tumour cytotoxicity in human lymphocytes by staphylococcal enterotoxin A.
    Lando PA; Hedlund G; Dohlsten M; Kalland T
    Cancer Immunol Immunother; 1991; 33(4):231-7. PubMed ID: 2059967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The tumor targeted superantigen ABR-217620 selectively engages TRBV7-9 and exploits TCR-pMHC affinity mimicry in mediating T cell cytotoxicity.
    Hedlund G; Eriksson H; Sundstedt A; Forsberg G; Jakobsen BK; Pumphrey N; Rödström K; Lindkvist-Petersson K; Björk P
    PLoS One; 2013; 8(10):e79082. PubMed ID: 24194959
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiple myeloma cells are killed by syndecan-1-directed superantigen-activated T cells.
    Ragnarsson L; Strömberg T; Wijdenes J; Tötterman TH; Weigelt C
    Cancer Immunol Immunother; 2001 Sep; 50(7):382-90. PubMed ID: 11676398
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody-targeted superantigens induce lysis of major histocompatibility complex class II-negative T-cell leukemia lines.
    Ihle J; Holzer U; Krull F; Dohlsten M; Kalland T; Niethammer D; Dannecker GE
    Cancer Res; 1995 Feb; 55(3):623-8. PubMed ID: 7530598
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting the human MUC1-C oncoprotein with an antibody-drug conjugate.
    Panchamoorthy G; Jin C; Raina D; Bharti A; Yamamoto M; Adeebge D; Zhao Q; Bronson R; Jiang S; Li L; Suzuki Y; Tagde A; Ghoroghchian PP; Wong KK; Kharbanda S; Kufe D
    JCI Insight; 2018 Jun; 3(12):. PubMed ID: 29925694
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel adenovirus expressing human 4-1BB ligand enhances antitumor immunity.
    Yoshida H; Katayose Y; Unno M; Suzuki M; Kodama H; Takemura S; Asano R; Hayashi H; Yamamoto K; Matsuno S; Kudo T
    Cancer Immunol Immunother; 2003 Feb; 52(2):97-106. PubMed ID: 12594573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monoclonal antibodies and superantigens: a novel therapeutic approach.
    Kalland T; Dohlsten M; Lind P; Sundstedt A; Abrahmsén L; Hedlund G; Björk P; Lando PA; Björklund M
    Med Oncol Tumor Pharmacother; 1993; 10(1-2):37-47. PubMed ID: 8258993
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes.
    Lamers CH; Gratama JW; Warnaar SO; Stoter G; Bolhuis RL
    Int J Cancer; 1995 Feb; 60(4):450-7. PubMed ID: 7829257
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel method for modification of tumor cells with bacterial superantigen with a heterobifunctional cross-linking agent in immunotherapy of cancer.
    Shimizu M; Matsuzawa A; Takeda Y
    Mol Biotechnol; 2003 Sep; 25(1):89-94. PubMed ID: 13679639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.